FDA Clearance Tracker · P200010-S032
Guardant360® CDx
Last checked: Nov 20, 2026Latest source record: Aug 7, 2026 (this decision)Source: openFDAMethods & limitations
Decided
Aug 7, 2026
Approved
Time to decision
28 days
Received Jul 10, 2026. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track No User Fee
Device class
Class III
The decision
- FDA number
- P200010-S032
- Device name
- Guardant360® CDx
- Applicant
- Guardant Health, Inc.
- Applicant location
- Redwood City, CA
- Received
- Jul 10, 2026
- Decided
- Aug 7, 2026
- Decision
- Approved
- Supplement type
- Normal 180 Day Track No User Fee
- Reason for supplement
- Postapproval Study Protocol
- Original approval
- P200010
Device type
- Device type
- Next generation sequencing oncology panel, somatic or germline variant detection system (PQP)
- Device class
- Class III
- Specialty
- Laboratory Medicine & Pathology
FDA's approval statement
As written in FDA's record.
Approval of the clinical protocol titled Clinical Validation of Guardant360 CDx for the Selection of First-Line Non-Small Cell Lung Cancer (NSCLC) Patients with ERBB2/HER2 TKD-Activating Mutations for Zongertinib Therapy (Protocol No. 01-LU-038, PLP-003941 R1, Version 1.0) for the post-approval study.
Source documents
Other decisions for Guardant Health, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
P250027 · Decided May 19, 2026 · 292 days after receipt
Device type: Next generation sequencing oncology panel, somatic or germline variant detection system (PQP) · Laboratory Medicine & Pathology
- Guardant360 CDxPMA supplement
P200010-S026 · Decided Jan 15, 2026 · 176 days after receipt · Panel Track
Device type: Next generation sequencing oncology panel, somatic or germline variant detection system (PQP) · Laboratory Medicine & Pathology
- Guardant360 CDxPMA supplement
P200010-S021 · Decided Sep 25, 2025 · 325 days after receipt · Panel Track
Device type: Next generation sequencing oncology panel, somatic or germline variant detection system (PQP) · Laboratory Medicine & Pathology
5 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.